BRPI0923556A2 - agente para o tratamento de estenose do canal espinhal - Google Patents

agente para o tratamento de estenose do canal espinhal

Info

Publication number
BRPI0923556A2
BRPI0923556A2 BRPI0923556A BRPI0923556A BRPI0923556A2 BR PI0923556 A2 BRPI0923556 A2 BR PI0923556A2 BR PI0923556 A BRPI0923556 A BR PI0923556A BR PI0923556 A BRPI0923556 A BR PI0923556A BR PI0923556 A2 BRPI0923556 A2 BR PI0923556A2
Authority
BR
Brazil
Prior art keywords
agent
treatment
spinal canal
canal stenosis
stenosis
Prior art date
Application number
BRPI0923556A
Other languages
English (en)
Portuguese (pt)
Inventor
Lothar Pache
Rudolf Reiter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0923556A2 publication Critical patent/BRPI0923556A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
BRPI0923556A 2008-12-23 2009-12-22 agente para o tratamento de estenose do canal espinhal BRPI0923556A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172859 2008-12-23
PCT/EP2009/067768 WO2010072774A2 (de) 2008-12-23 2009-12-22 Mittel zur behandlung der spinalkanalstenose

Publications (1)

Publication Number Publication Date
BRPI0923556A2 true BRPI0923556A2 (pt) 2016-01-26

Family

ID=40527906

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923556A BRPI0923556A2 (pt) 2008-12-23 2009-12-22 agente para o tratamento de estenose do canal espinhal

Country Status (11)

Country Link
EP (1) EP2367543A2 (zh)
JP (1) JP2012513446A (zh)
KR (1) KR20110098965A (zh)
CN (1) CN102271667A (zh)
AU (1) AU2009331469A1 (zh)
BR (1) BRPI0923556A2 (zh)
CA (1) CA2748163A1 (zh)
IL (1) IL213768A0 (zh)
MX (1) MX2011006852A (zh)
SG (1) SG172315A1 (zh)
WO (1) WO2010072774A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016209492B2 (en) 2015-01-20 2020-10-22 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
AU2018275873A1 (en) 2017-06-01 2019-12-19 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1123704T3 (da) 1998-09-01 2004-11-01 Nissan Chemical Ind Ltd Midler til spinalstenose
WO2004043491A1 (ja) 2002-11-14 2004-05-27 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
WO2004089411A1 (ja) 2003-04-03 2004-10-21 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
DE102006013307B3 (de) 2006-03-21 2007-10-04 Ergonex Pharma Gmbh Tergurid/Protergurid zur Behandlung von chronischen Schmerzen

Also Published As

Publication number Publication date
SG172315A1 (en) 2011-07-28
CN102271667A (zh) 2011-12-07
EP2367543A2 (de) 2011-09-28
AU2009331469A1 (en) 2011-07-21
KR20110098965A (ko) 2011-09-02
WO2010072774A3 (de) 2010-09-23
IL213768A0 (en) 2011-07-31
WO2010072774A2 (de) 2010-07-01
CA2748163A1 (en) 2010-07-01
JP2012513446A (ja) 2012-06-14
MX2011006852A (es) 2011-07-20

Similar Documents

Publication Publication Date Title
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
SI2292231T1 (sl) Terapevtsko sredstvo za stenozo spinalnega kanala
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0920030A2 (pt) agente de oclusão do tecido
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0819361A2 (pt) Composição de tratamento de cabelos e agente de tratamento
BRPI0924622A2 (pt) composições para tratamento de tecidos, processo de fabricação, e método de uso.
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0807730A2 (pt) Método de condicionamento de tecidos e composição sólida para tratamento de tecidos
BRPI0719089A2 (pt) Método de tratamento de tecido e composição para transmitir hidrofobicidade diferencial
BRPI0914454A2 (pt) "composição para o tratamento do tecido epitelial"

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]